Treatment with a TKI is recommended for the initial treatment of NSCLC patients with a driver oncogene, and almost all patients with a driver oncogene, except EGFR exon 20 insertion, were pre-treated with a TKI in this study. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.